Navigation Links
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Date:7/30/2008

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

"This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. Mathers, President and CEO of Peptimmune. "The '790 patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases."

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and eff
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... N.J. , July 1, 2015  Echo ... device company focused on non-invasive continuous glucose monitoring ... its new and completely re-designed corporate website ... intuitive access to Echo,s technology and enhances the ... The new website better communicates to prospective customers ...
(Date:7/1/2015)... HEIGHTS, Utah , July 1, 2015 /PRNewswire/ ... ), a manufacturer and marketer of rehabilitation and ... completed its $4,025,000 private placement financing led by ... strategic private equity investor focused on the healthcare ... to promote organic growth and pursue potential strategic ...
(Date:7/1/2015)... , July 1, 2015 ExeGi Pharma, ... and probiotic treatments, announced today that it has been ... and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome™ ... Visbiome was developed by Professor Claudio De Simone ... extensive clinical investigation. Professor De Simone recently signed an ...
Breaking Medicine Technology:Echo Therapeutics Announces New Website Launch 2Echo Therapeutics Announces New Website Launch 3Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
(Date:7/1/2015)... ... July 01, 2015 , ... ... products, is helping families get ready for Independence Day celebrations with new takes ... easy and versatile options are perfect for any summertime get together. , “Celebrating ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... their big summer sale. Customers purchasing two or more Bunion Booties directly ... , Bunion Bootie temporarily corrects misaligned toes and its ultra thin ...
(Date:7/1/2015)... ... ... wasn’t always a steadfast supporter of plastic surgery. But just as her career in ... terrible car accident years ago left her injured and in need of reconstructive surgery ... if I Do?): Answers to All Your Questions about Plastic Surgery” (published by Archway Publishing), ...
(Date:7/1/2015)... ... 01, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Citizens Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/1/2015)... ... 2015 , ... Who doesn’t want a life filled with thriving positivity and ... between work and life, and positive friendships and relationships? , Dr. Marsha W. ... Wellbeing in Doctors. , With a focus on solving the epidemic of ill-being in ...
Breaking Medicine News(10 mins):Health News:Boar’s Head Helps Craft a Delicious Independence Day 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 3Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:Medical Doctor Explains The Healthy Effects of a Positive Outlook in New Book 2
... genetics-based explanation for the causes of anorexia nervosa were ... illness than those given a sociocultural explanation, a University ... This is a potentially important finding, said first author ... of information about the biological and genetic underpinnings of ...
... /Xinhua-PRNewswire/ -- Sundia MediTech,(Shanghai) Company recently announced a welcome ... Zhu and Dr. Shu Gao. Dr. Zhu is appointed ... as the Vice,President in charge of Chemical Synthesis business., ... his college,education in chemistry in Nanjing University in China. ...
... will release its fourth quarter and year-end 2007 financial ... The earnings,release will be available on the PPD Web ... On Thursday, February 7, 2008, at 9 a.m. EST, ... to discuss financial results and the,overall business environment. A ...
... CDC Prepares to Release Alarming New HIV Rates; ... Jan. 10 AIDS Healthcare,Foundation (AHF) today urged ... million of proposed budget cuts in AIDS services,that ... services for,Californians living with HIV/AIDS as he seeks ...
... that Program Integrity will,be Needlessly Compromised in the Interim, ... today applauded the Centers for Medicare and Medicaid,Services (CMS) ... need to be accredited, but expressed concern that it ... be fully implemented. The PMC,however, further commends CMS for ...
... for when antiviral drugs fail , , THURSDAY, Jan. 10 ... human proteins that help HIV propagate, creating hope for ... , Using a technique called RNA interference to screen ... according to the study published online Jan. 10 in ...
Cached Medicine News:Health News:People with anorexia less likely to be blamed when biology, genetics explained 2Health News:People with anorexia less likely to be blamed when biology, genetics explained 3Health News:CRO Company Sundia Welcomes New Members to Its Executive Team 2Health News:PPD Announces Fourth Quarter and Year-End 2007 Earnings Release, Webcast and Conference Call 2Health News:AHF to Schwarzenegger: 'AIDS Cuts Are Deadly' 2Health News:AHF to Schwarzenegger: 'AIDS Cuts Are Deadly' 3Health News:Mandatory Accreditation Delayed Until September 2009 2Health News:New Proteins That Help HIV Grow Identified 2
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
Mayo Medical Laboratories (MML) is the diagnostic reference laboratory for Mayo Clinic. MML specializes in esoteric laboratory testing for health care organizations throughout the United States and a...
Medicine Products: